Use of electronic labeling
Medical product information is designed with the intent to ensure prescription and non-prescription healthcare products are used in an effective and safe manner.
This information is a culmination of clinical development data and post-marketing learnings and data, translated into descriptive text for Healthcare Professionals (HCPs) and in some cases specifically for the patient.
It plays a pivitol role in ensuring patient’s understanding of their treatments while also supporting HCPs in their decision making.
To make this information even more effective, new, digital-enabled tools for delivery of labeling that facilitate access, understanding and usability are key components in enabling more effective use of available treatments and helping raise overall health literacy.
Related news and resources
IFPMA-INTERFARMA-FIFARMA statement on the Rio de Janeiro Declaration of the G20 Health Ministers
The innovative pharmaceutical industry, represented by IFPMA, INTERFARMA and FIFARMA reiterates its commitment to the G20 health priorities, reaffirmed in the Rio de Janeiro Declaration.
Read moreWHO EMRO RC71: Regional flagship initiative 1: Expanding equitable access to medical products
On 14 October 2024 in Doha, Qatar, IFPMA delivered a statement at the 71st session of the WHO EMRO Regional Committee on the Regional flagship initiative 1: Expanding equitable access to medical products.
Read moreThe Value of Reference Agency Assessment Reports in Enabling Regulatory Reliance
Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was reviewed by the reference NRA, provides a rationale for decision making and promotes confidence and trust. The Centre for Innovation in Regulatory Science (CIRS) has published...
Read more